Search Content | UT Health San Antonio MD Anderson Cancer Center

Search Result for "Breast Cancer"

Clinical Trial

A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of
Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous

This is a Phase 2, randomized, active-controlled, parallel-group, multisite, open-label studyof belzutifan plus fulvestrant versus everolimus plus ETPC (fulvestrant or exemestane) inparticipants with ER+/HER2- unresectable, locally advanced, or mBC.

Clinical Trial

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

This is a Phase 3, global, multicenter, randomized, open-label study.

Research & Publications

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Breast Oncology Preceptorship

provider

Charles Fries, MD Plastic Surgery

Story

Cancer patients are getting younger. Mays Cancer Center experts explain the modern factors at play

The risk of aging-related diseases, including cancer, doesn't sharply increase until the age of 50. Why then are so many younger people getting cancer right now?

provider

Carissia Calvo–Strube, M.D. Surgical Oncology, Breast Surgical Oncology

Apr

Event